Trial
NCT04989413
Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg Vs Placebo As Adjuvant Treatment in Chronic Migraine -
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Hospital Israelita Albert Einstein
Collaborators
Industria Farmacêutica Health Meds
Condition
Chronic Migraine, Headache
Intervention
Placebo oral drops
Why stopped
an interim analysis to rule out futility was positive, we completed active patients and stopped recruitment with 75 patients enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-24